Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 4
2014 1
2015 2
2016 1
2017 2
2018 2
2019 1
2020 8
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Patch AM, et al. Among authors: au yeung g. Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Nature. 2015. PMID: 26017449
Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Nan Tie E, Lai-Kwon J, Rtshiladze MA, Na L, Bozzi J, Read T, Atkinson V, Au-Yeung G, Long GV, McArthur GA, Sandhu S, Saw R, Walpole E, Menzies A, Smithers M, Gyorki DE. Nan Tie E, et al. Among authors: au yeung g. J Immunother Cancer. 2020 May;8(1):e000440. doi: 10.1136/jitc-2019-000440. J Immunother Cancer. 2020. PMID: 32376722 Free PMC article.
The molecular origin and taxonomy of mucinous ovarian carcinoma.
Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL. Cheasley D, et al. Among authors: au yeung g. Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x. Nat Commun. 2019. PMID: 31477716 Free PMC article.
i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A, Gough K, Murnane A, Au-Yeung G, Dawson T, Pearson E, Dhillon H, Sandhu S, Williams N, Paton E, Billett A, Traill A, Andersen H, Beedle V, Milne D. Hyatt A, et al. Among authors: au yeung g. BMJ Open. 2020 Feb 28;10(2):e036059. doi: 10.1136/bmjopen-2019-036059. BMJ Open. 2020. PMID: 32114479 Free PMC article. Clinical Trial.
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Weppler AM, Pattison A, Bhave P, De Ieso P, Raleigh J, Hatzimihalis A, Gill AJ, Balachander S, Callahan J, Chua M, Au-Yeung G, McArthur GA, Hicks RJ, Tothill RW, Sandhu S. Weppler AM, et al. Among authors: au yeung g. J Immunother Cancer. 2020 Oct;8(2):e000700. doi: 10.1136/jitc-2020-000700. J Immunother Cancer. 2020. PMID: 33060145 Free PMC article.
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Among authors: au yeung g. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Sivakumaran T, Mileshkin L, Grant P, Na L, DeFazio A, Friedlander M, Obermair A, Webb PM, Au-Yeung G; OPAL Study Group. Sivakumaran T, et al. Among authors: au yeung g. Gynecol Oncol. 2020 Jul;158(1):47-53. doi: 10.1016/j.ygyno.2020.04.706. Epub 2020 May 4. Gynecol Oncol. 2020. PMID: 32381362
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page